Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 17/20 | 1.00 |
| ▸ | EPAS1 | Q99814 | 15/20 | 1.00 |
| ▸ | EP300 | Q09472 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | COXFA4 | O00483 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2561679 | 0.80 | HIF1A (0.68) | HIF1AEPAS1EP300 | |
| SCHEMBL12291918 | 0.79 | HIF1A (0.66) | HIF1AEPAS1EP300MAPT | |
| SCHEMBL14178660 | 0.78 | HIF1A (0.63) | HIF1AEPAS1 | |
| SCHEMBL16694306 | 0.77 | HIF1A (0.62) | HIF1AEPAS1ALDH1A1COXFA4 | |
| SCHEMBL2564588 | 0.77 | HIF1A (0.62) | HIF1AEPAS1ALDH1A1MAPTCOXFA4 | |
| SCHEMBL2560364 | 0.76 | HIF1A (1.00) | HIF1AEPAS1EP300 | |
| SCHEMBL14930293 | 0.76 | HIF1A (0.61) | HIF1AEPAS1 | |
| SCHEMBL14178661 | 0.75 | HIF1A (0.60) | HIF1AEPAS1 | |
| SCHEMBL14139154 | 0.75 | HIF1A (0.60) | HIF1AEPAS1EP300KDM4EMAPT | |
| SCHEMBL16694474 | 0.75 | HIF1A (0.67) | HIF1AEPAS1ALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9062072-B2 | Inhibitors of HIF and angiogenesis | EMORY UNIVERSITY (US) | 2015-06-23 | — | — | US | disclosed |
| US-20130116275-A1 | INHIBITORS OF HIF AND ANGIOGENESIS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-05-09 | — | — | US | disclosed |
| WO-2011133659-A2 | INHIBITORS OF HIF AND ANGIOGENESIS | EMORY UNIVERSITY (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116275-A1 | INHIBITORS OF HIF AND ANGIOGENESIS | HIF1AN, HIF1A, EGLN2 | HIF1A 2/4885EPAS1 16/4885EP300 1698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.